Although ALDH1A3 is associated with increased tumor progression and worse prognosis in many cancer types, increased ALDH1A3 expression has also been associated with better patient outcomes in TP53 wildtype ovarian tumors, BRAF-mutated metastatic melanoma, and non-small cell lung cancer [39,54,55]. Here, ALDH1A3 is linked to metastatic melanoma.